Abstract:Ischemic stroke, as a prevalent neurological disorder, often results in rapid increases in the production of reactive oxygen species (ROS) and inflammatory factors in the focal ischemic area. Though edaravone is an approved treatment, its effect is limited due to its weak ability to cross the blood-brain barrier (BBB) and short half-life. Other effective pharmacological treatment options are clearly lacking. In this study, PNIVDBrF-3-Eda (also named MG-3-Eda) was prepared using a thermo- and pH dual-responsive PNIVDBrF microgel. These were designed with a positively charged network, as synthesized by simultaneous quaternization cross-linking and surfactant-free emulsion copolymerization, to be loaded with the negatively charged edaravone. We then investigated whether such a targeted delivery of edaravone could provide enhanced neuroprotection. Cytotoxicity assays confirmed that the microgel (<1 mg/mL) exhibited promising cytocompatibility with no remarkable effect on cell viability, cell cycle regulation, or apoptosis levels. In vitro and in vivo experiments demonstrated that the microgels could successfully penetrate the blood-brain barrier where efficient BBB crossing was observed after disruption of the BBB due to ischemic injury. This enabled MG-3-Eda to target the cerebral ischemic area and achieve local release of edaravone. Treatment with MG-3-Eda significantly reduced the cerebral infarct area in transient middle cerebral artery occlusion (tMCAO) mice and significantly improved behavioral scores. MG-3-Eda treatment also prevented the reduction in NF200 expression, a neuronal marker protein, and attenuated microglia activation (as detected by Iba1) in the local ischemic area via local antioxidant and anti-inflammatory effects. A superior neuroprotective effect was noted for MG-3-Eda compared to that for free edaravone. Our results indicate that MG-3-Eda administration represents a clear potential treatment for cerebral ischemia via its targeted delivery of edaravone to ischemic areas where it provides significant local antioxidant and anti-inflammatory effects.

Fast, Non-Competitive and Reversible Inhibition of Nmda-Activated Currents by 2-Bfi Confers Neuroprotection

2-(-2-Benzofuranyl)-2-imidazoline Induces Bcl-2 Expression and Provides Neuroprotection Against Transient Cerebral Ischemia in Rats

The Dream Protein Negatively Regulates The Nmda Receptor Through Interaction With The Nr1 Subunit

Brain Protection Conferred by Long-Term Administration of 2-(2-benzofuranyl)-2-imidazoline Against Experimental Autoimmune Encephalomyelitis

Neurovascular Protection Conferred by 2-BFI Treatment During Rat Cerebral Ischemia

Attenuation Of Ischemia-Induced Rat Brain Injury By 2-(-2-Benzofuranyl)-2-Imidazoline, A High Selectivity Ligand For Imidazoline I-2 Receptors

Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents

Reversible Inhibition of Intracellular Calcium Influx Through NMDA Receptors by Imidazoline I(2) Receptor Antagonists.

The 2-(2-benzofuranyl)-2-imidazoline provides neuroprotection against focal cerebral ischemia-reperfusion injury in diabetic rats: Influence of microglia and possible mechanisms of action

Bq-869, A Novel Nmda Receptor Antagonist, Protects Against Excitotoxicity and Attenuates Cerebral Ischemic Injury in Stroke

Pathologically activated neuroprotection via uncompetitive blockade of N-methyl-D-aspartate receptors with fast off-rate by novel multifunctional dimer bis(propyl)-cognitin

A Promising Dual-functional Neuroprotective Derivative of Memantine

Targeted Therapy of Ischemic Stroke Via Crossing the Blood-Brain Barrier Using Edaravone-Loaded Multiresponsive Microgels.

2-BFI Attenuates Experimental Autoimmune Encephalomyelitis-Induced Spinal Cord Injury with Enhanced B-CK, CaATPase, but Reduced Calpain Activity.

Neuroprotective effects of MK-801 against cerebral ischemia reperfusion

Dl-3-n-butylphthalide attenuates cerebral ischemia/reperfusion injury in mice through AMPK-mediated mitochondrial fusion

Discovery of benzyloxy benzamide derivatives as potent neuroprotective agents against ischemic stroke

Protective Effect of Adenosine A2B Receptor Agonist, BAY60-6583, Against Transient Focal Brain Ischemia in Rat

2-iminobiotin, a selective inhibitor of nitric oxide synthase, improves memory and learning in a rat model after four vessel occlusion, mimicking cardiac arrest

Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model

Cerebroside-A Provides Potent Neuroprotection After Cerebral Ischaemia Through Reducing Glutamate Release And Ca2+ Influx Of Nmda Receptors